Issued by Alexion Pharmaceuticals
Alexion Pharmaceuticals (NASDAQ: ALXN), a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the discovery, development and commercialization of life-changing medicines, releases its inaugural corporate social responsibility (CSR) report, Brighter Futures.
March 30, 2020 - Alexion Pharmaceuticals (NASDAQ: ALXN), a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the discovery, development and commercialization of life-changing medicines, releases its inaugural corporate social responsibility (CSR) report, Brighter Futures.
As this report focuses on 2019, it does not contain information about the company’s approach to the current COVID-19 pandemic. Information on Alexion’s response to this global health crisis can be found on its website.
“At Alexion, we work to change lives for the better – ours, people living with rare diseases and the communities we serve – and our commitment to being a responsible corporate citizen helps make it possible,” said Ludwig Hantson, Ph.D., Chief Executive Officer of Alexion.
The 2019 CSR Report is organized along Alexion’s CSR-STAR Platform, which sets forth the key principles of its comprehensive CSR approach: Serve Communities and Sustain Our Planet, Transform Patient Lives, Advance Our People and Our Company, and Redefine What It Means to Live With a Rare Disease. All of these principles are built upon a Foundation of Ethics and Compliance.
The report sets forth a set of aspirations that align with each focus area, along with metrics for measuring progress against each. These include:
SERVE Communities and Sustain Our Planet
Make a positive impact in our communities
Increase year-over-year engagement in Global Day of Service, our primary employee volunteer event
Be responsible stewards of our shared environment
Reduce greenhouse gas emissions (absolute and intensity)
Increase amount of water recycled and reused
Maintain zero process waste-to-landfill enterprise-wide year over year
TRANSFORM Patient Lives
Support people affected by rare and devastating diseases and their caregivers throughout the patient journey
Increase the percentage of eligible patients who have been diagnosed with a disease that Alexion treats, that are included in Alexion patient support programs year over year, regardless of whether they are using our therapies
Ensure that, where possible, ongoing and new patient support programs have patient organizations involved in development, design and implementation
Generate real-world evidence to document the benefits and safety of Alexion treatments
Ensure that, where possible, Alexion seeks patients’ input on its rare disease registries regarding data collection, analysis and publication, and acknowledge patient authorship
Include patient and caregiver perspective, advice and input into early clinical development plans and identified Phase II/III Alexion clinical trials to inform protocols and where possible, patients’ informed consent documents
Be a key influencer of patient organization engagement standards across the industry through ongoing, proactive thought leadership
ADVANCE Our People and Our Company
Become the most rewarding company to work for
Implement key culture initiatives to drive patient-centricity year over year
Advance employee experience priorities to drive patient-centricity year over year
Create more patient-centric decision-making
REDEFINE What it Means to Live With a Rare Disease
Advance healthcare through new therapies and innovative diagnostics
Accelerate diagnostics for rare disease patients by creating or optimizing new tests for the patient community, year over year
Pursue programs to bring novel therapies to patients, year over year
ETHICS & COMPLIANCE: Our Foundation
Build trust through ethics, quality and compliance
Be a key influencer of compliance standards across the industry through ongoing, proactive thought leadership
Alexion is already delivering on many of these aspirations, a sampling of which are highlighted below and in Brighter Futures.
Serve Communities and Sustain Our Planet:
Transform Patient Lives:
Advance Our People and Our Company:
Redefine What It Means to Live With a Rare Disease:
Ethics and Compliance, Our Foundation:
Learn more by accessing the full Alexion 2019 CSR Report at csr.alexion.com.
Further information about Alexion can be found at www.alexion.com.
Megan Goulart, 857-338-8634
Senior Director, Corporate Communications
Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the discovery, development and commercialization of life-changing therapies. As the global leader in complement biology and inhibition for more than 20 years